Calidi Biotherapeutics reports preclinical data: systemic RTNova platform delivers gene therapy payload to tumors

Calidi Biotherapeutics, Inc.

RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.
Single dose of 3KO RT with immunotherapeutic payload increased leukocyte infiltration to 92% vs 46% untreated.
Complete eradication of certain tumors observed in preclinical model after treatment with 3KO RT plus payload.
Platform also acts as a viral vector to express therapeutic genes at tumor sites; potential partnerships noted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.